JP2005508916A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508916A5 JP2005508916A5 JP2003531968A JP2003531968A JP2005508916A5 JP 2005508916 A5 JP2005508916 A5 JP 2005508916A5 JP 2003531968 A JP2003531968 A JP 2003531968A JP 2003531968 A JP2003531968 A JP 2003531968A JP 2005508916 A5 JP2005508916 A5 JP 2005508916A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- composition according
- replication
- dna plasmid
- defective adenovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 113
- 241000701161 unidentified adenovirus Species 0.000 claims 73
- 239000013612 plasmid Substances 0.000 claims 72
- 230000003834 intracellular effect Effects 0.000 claims 60
- 108090000288 Glycoproteins Proteins 0.000 claims 49
- 102000003886 Glycoproteins Human genes 0.000 claims 49
- 108020004707 nucleic acids Proteins 0.000 claims 49
- 102000039446 nucleic acids Human genes 0.000 claims 49
- 150000007523 nucleic acids Chemical class 0.000 claims 49
- 230000004927 fusion Effects 0.000 claims 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims 40
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims 39
- 230000002068 genetic effect Effects 0.000 claims 32
- 102000004961 Furin Human genes 0.000 claims 30
- 108090001126 Furin Proteins 0.000 claims 30
- 238000003776 cleavage reaction Methods 0.000 claims 30
- 230000007017 scission Effects 0.000 claims 30
- 230000002950 deficient Effects 0.000 claims 27
- 230000010076 replication Effects 0.000 claims 27
- 108010061100 Nucleoproteins Proteins 0.000 claims 20
- 102000011931 Nucleoproteins Human genes 0.000 claims 20
- 230000037452 priming Effects 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 241001115401 Marburgvirus Species 0.000 claims 13
- 241001115402 Ebolavirus Species 0.000 claims 10
- 210000004899 c-terminal region Anatomy 0.000 claims 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 10
- 230000037430 deletion Effects 0.000 claims 10
- 238000012217 deletion Methods 0.000 claims 10
- 108020004705 Codon Proteins 0.000 claims 9
- 206010023927 Lassa fever Diseases 0.000 claims 9
- 241000700605 Viruses Species 0.000 claims 9
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 230000028993 immune response Effects 0.000 claims 6
- 102000007999 Nuclear Proteins Human genes 0.000 claims 5
- 108010089610 Nuclear Proteins Proteins 0.000 claims 5
- 230000009977 dual effect Effects 0.000 claims 5
- 101900102527 Lake Victoria marburgvirus Nucleoprotein Proteins 0.000 claims 4
- 241000271566 Aves Species 0.000 claims 2
- 101710141454 Nucleoprotein Proteins 0.000 claims 2
- 241000700618 Vaccinia virus Species 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 238000002649 immunization Methods 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 241001529453 unidentified herpesvirus Species 0.000 claims 2
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- 241001430294 unidentified retrovirus Species 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
Images
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32647601P | 2001-10-01 | 2001-10-01 | |
| PCT/US2002/030251 WO2003028632A2 (en) | 2001-10-01 | 2002-09-24 | Development of a preventive vaccine for filovirus infection in primates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005280131A Division JP4198148B2 (ja) | 2001-10-01 | 2005-09-27 | 霊長類におけるフィロウイルス感染に対する予防ワクチンの開発 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005508916A JP2005508916A (ja) | 2005-04-07 |
| JP2005508916A5 true JP2005508916A5 (https=) | 2006-10-12 |
Family
ID=23272371
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003531968A Pending JP2005508916A (ja) | 2001-10-01 | 2002-09-24 | 霊長類におけるフィロウイルス感染に対する予防ワクチンの開発 |
| JP2005280131A Expired - Lifetime JP4198148B2 (ja) | 2001-10-01 | 2005-09-27 | 霊長類におけるフィロウイルス感染に対する予防ワクチンの開発 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005280131A Expired - Lifetime JP4198148B2 (ja) | 2001-10-01 | 2005-09-27 | 霊長類におけるフィロウイルス感染に対する予防ワクチンの開発 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US7635688B2 (https=) |
| EP (1) | EP1504112A4 (https=) |
| JP (2) | JP2005508916A (https=) |
| AT (1) | ATE396739T1 (https=) |
| AU (1) | AU2002327049B2 (https=) |
| CA (4) | CA2776391C (https=) |
| DE (1) | DE60226911D1 (https=) |
| ES (1) | ES2307093T3 (https=) |
| WO (1) | WO2003028632A2 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1654370T3 (en) | 2003-08-01 | 2018-08-20 | Government Of The Us Secretary Department Of Health And Human Services | ACCELERATED EBOLA VACCINATION |
| WO2005034992A2 (en) * | 2003-09-15 | 2005-04-21 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv vaccines based on env of multiple clades of hif |
| US20070207461A1 (en) | 2004-02-23 | 2007-09-06 | Crucell Holland B.V. | Virus Purification Methods |
| US7504243B2 (en) | 2004-03-19 | 2009-03-17 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for the production of biliverdin |
| AU2005243730B2 (en) * | 2004-04-12 | 2010-05-27 | Genvec, Inc. | Method of using adenoviral vectors to induce an immune response |
| AU2005274948B2 (en) * | 2004-07-16 | 2011-09-22 | Genvec, Inc. | Vaccines against aids comprising CMV/R-nucleic acid constructs |
| EP1797113B1 (en) * | 2004-09-27 | 2014-11-26 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Optimized vaccines to provide protection against ebola and other viruses |
| CA2602944C (en) | 2005-04-11 | 2015-08-11 | Crucell Holland B.V. | Virus purification using ultrafiltration |
| EP1877087B1 (en) | 2005-04-15 | 2013-02-20 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
| US20070185025A1 (en) * | 2005-09-11 | 2007-08-09 | The Trustees Of Columbia University In The City Of New York | Filoviral immunosuppressive peptides and uses thereof |
| US7947286B2 (en) * | 2005-10-07 | 2011-05-24 | Panthera Biopharma Llc | Drosophila cell lines producing recombinant secretable filovirus surface glycoproteins lacking the membrane spanning domain |
| KR20090034297A (ko) * | 2006-02-16 | 2009-04-07 | 더 거번먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 레프리젠티드 바이 더 세크러터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 | 인플루엔자에 대한 항바이러스제 및 백신 |
| EP2333091B1 (en) | 2007-05-29 | 2017-06-21 | Nature Technology Corporation | Vectors and methods for genetic immunization |
| WO2009092038A1 (en) * | 2008-01-16 | 2009-07-23 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Influenza dna vaccination and methods of use thereof |
| US8404263B2 (en) | 2008-06-20 | 2013-03-26 | Basf Se | Agrochemical formulations comprising a pesticide, an organic UV-photoprotective filter and coated metal-oxide nanoparticles |
| EP3351628B1 (en) | 2008-10-24 | 2023-07-26 | The Government of The United States of America as represented by The Secretary, Department of Health and Human Services | Human ebola virus species and compositions and methods thereof |
| EP2370455B1 (en) | 2008-11-26 | 2019-07-03 | Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Virus like particle compositions and methods of use |
| WO2010062861A2 (en) | 2008-11-26 | 2010-06-03 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
| WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
| US20120219584A1 (en) | 2009-10-05 | 2012-08-30 | The United States Of America As Represented By The Secretary, Department Of Health | Protection against pandemic and seasonal strains of influenza |
| US9125411B2 (en) | 2010-04-15 | 2015-09-08 | Basf Se | UV absorbers for reducing the E/Z isomerization of pesticides |
| US9526777B2 (en) | 2010-04-16 | 2016-12-27 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein |
| ES2552657T3 (es) | 2010-05-26 | 2015-12-01 | Satiogen Pharmaceuticals, Inc. | Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias |
| DK2655604T3 (en) | 2010-12-14 | 2018-08-06 | Us Gov Health & Human Services | ADENOVIRUS SEROTYPE-26- AND SEROTYPE-35-FILOVIRUS VACCINES |
| US9402891B2 (en) * | 2011-06-08 | 2016-08-02 | Ohio State Innovation Foundation | Norovirus immunogens and related materials and methods |
| KR102314421B1 (ko) * | 2011-07-11 | 2021-10-19 | 이노비오 파마수티컬즈, 인크. | 교차-보호성 아레나바이러스 백신 및 이의 사용 방법 |
| EP2758038B1 (en) | 2011-09-23 | 2018-05-30 | The United States of America, as represented by The Secretary, Department of Health & Human Services | Novel influenza hemagglutinin protein-based vaccines |
| US20130108573A1 (en) | 2011-10-28 | 2013-05-02 | Lumena Pharmaceuticals, Inc. | Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease |
| AU2012328526B2 (en) | 2011-10-28 | 2017-05-25 | Shire Human Genetic Therapies, Inc. | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
| CA3194125A1 (en) * | 2012-04-12 | 2013-10-17 | The Trustees Of The University Of Pennsylvania | Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same |
| WO2015054639A1 (en) | 2013-10-11 | 2015-04-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Epstein-barr virus vaccines |
| TWI516602B (zh) | 2013-10-29 | 2016-01-11 | 臺北醫學大學 | 高通量篩選高表現細胞之方法及由其篩選之細胞 |
| US10363301B2 (en) | 2014-05-27 | 2019-07-30 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Stabilized influenza hemagglutinin stem region trimers and uses thereof |
| EP3188752A2 (en) * | 2014-09-03 | 2017-07-12 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine |
| US11191727B2 (en) | 2014-12-31 | 2021-12-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Multivalent nanoparticle-based vaccines |
| SG11201705782QA (en) * | 2015-01-28 | 2017-08-30 | Integrated Biotherapeutics Inc | Equine immunoglobulin compositions and uses for treating filovirus-mediated diseases |
| EP3383426A1 (en) | 2015-12-04 | 2018-10-10 | Dana Farber Cancer Institute, Inc. | Vaccination with mica/b alpha 3 domain for the treatment of cancer |
| US11459619B2 (en) | 2016-02-08 | 2022-10-04 | The Johns Hopkins University | Handheld nucleic acid-based assay for rapid identification |
| SG10201912944QA (en) | 2016-09-02 | 2020-02-27 | The Usa As Represented By The Secretary | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof |
| EP3661549A1 (en) | 2017-08-02 | 2020-06-10 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Hepatitis b nanoparticle-based vaccine for influenza virus |
| CA3100070A1 (en) * | 2018-05-18 | 2019-11-21 | Universite Laval | Vectors for dna vaccination |
| CN113423718A (zh) | 2019-02-08 | 2021-09-21 | 美国政府(由卫生和人类服务部的部长所代表) | 基于纳米颗粒的流感病毒疫苗及其用途 |
| EP4637808A1 (en) | 2022-12-22 | 2025-10-29 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Stabilized pfs48/45 proteins and uses thereof |
| WO2025184403A2 (en) * | 2024-02-29 | 2025-09-04 | Memorial Sloan-Kettering Cancer Center | Cell penetrating peptides and methods including the same |
| CN121494944A (zh) * | 2026-01-13 | 2026-02-10 | 中国人民解放军军事科学院军事医学研究院 | 一种马尔堡gp蛋白突变体、dna分子、重组载体及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6171596B1 (en) * | 1993-12-10 | 2001-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Oligomeric HIV-1 envelope glycoproteins |
| US6027881A (en) | 1996-05-08 | 2000-02-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence |
| US6200959B1 (en) * | 1996-12-04 | 2001-03-13 | Powerject Vaccines Inc. | Genetic induction of anti-viral immune response and genetic vaccine for filovirus |
| WO1999032147A1 (en) | 1997-12-23 | 1999-07-01 | The Regents Of The University Of Michigan | Immunization for ebola virus infection |
| AU7089600A (en) | 1999-08-30 | 2001-03-26 | U.S. Army Medical Research Institute Of Infectious Diseases | Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein |
-
2002
- 2002-09-24 CA CA 2776391 patent/CA2776391C/en not_active Expired - Lifetime
- 2002-09-24 DE DE60226911T patent/DE60226911D1/de not_active Expired - Lifetime
- 2002-09-24 JP JP2003531968A patent/JP2005508916A/ja active Pending
- 2002-09-24 ES ES05013732T patent/ES2307093T3/es not_active Expired - Lifetime
- 2002-09-24 AT AT05013732T patent/ATE396739T1/de not_active IP Right Cessation
- 2002-09-24 CA CA2462455A patent/CA2462455C/en not_active Expired - Lifetime
- 2002-09-24 WO PCT/US2002/030251 patent/WO2003028632A2/en not_active Ceased
- 2002-09-24 CA CA2776522A patent/CA2776522C/en not_active Expired - Lifetime
- 2002-09-24 EP EP02761814A patent/EP1504112A4/en not_active Ceased
- 2002-09-24 AU AU2002327049A patent/AU2002327049B2/en not_active Expired
- 2002-09-24 US US10/491,121 patent/US7635688B2/en not_active Expired - Lifetime
- 2002-09-24 CA CA2776272A patent/CA2776272C/en not_active Expired - Lifetime
-
2004
- 2004-11-24 US US10/997,120 patent/US7094598B2/en not_active Expired - Lifetime
-
2005
- 2005-09-27 JP JP2005280131A patent/JP4198148B2/ja not_active Expired - Lifetime
-
2009
- 2009-11-04 US US12/612,621 patent/US8106027B2/en not_active Expired - Fee Related
- 2009-11-04 US US12/612,625 patent/US8124592B2/en not_active Expired - Fee Related
- 2009-11-04 US US12/612,579 patent/US8106026B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005508916A5 (https=) | ||
| CA2462455A1 (en) | Development of a preventive vaccine for filovirus infection in primates | |
| Ulmer et al. | DNA vaccines | |
| Winter et al. | The structure of the gene encoding the nucleoprotein of human influenza virus A/PR/8/34 | |
| Wang et al. | Enhanced type I immune response to a hepatitis B DNA vaccine by formulation with calcium-or aluminum phosphate | |
| US5916879A (en) | DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof | |
| JP2004527213A5 (https=) | ||
| GB2610070A (en) | Coronavirus vaccine formulations | |
| JP2018524393A5 (https=) | ||
| CN1154069A (zh) | 多表位疫苗 | |
| JP2013501038A5 (https=) | ||
| CA2293692A1 (en) | Methods and reagents for vaccination which generate a cd8 t cell immune response | |
| JP2014527404A5 (https=) | ||
| WO2006037038B1 (en) | Optimized vaccines to provide protection against ebola and other viruses | |
| JP2004533208A5 (https=) | ||
| BR112015023524B1 (pt) | Vírus vaccinia ankara modificado, composição compreendendo o dito vírus e uso do mesmo para primagem ou reforço de uma resposta imune | |
| JP2024511412A5 (https=) | ||
| JP2024508683A5 (https=) | ||
| JP2003509470A5 (https=) | ||
| Rollier et al. | Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting | |
| BR112020012273A2 (pt) | métodos e composições para induzir uma resposta imune contra o vírus da hepatite b (hbv) | |
| US20090104213A1 (en) | Vaccine for House Dust Mite Allergen Using Naked DNA | |
| CN1874787B (zh) | 预防/治疗hbv感染和hbv介导疾病的组合物 | |
| Ramsay et al. | DNA immunization | |
| JP2020522249A5 (https=) |